Table 3.
Subtheme | Harm Reduction Documents | Guideline Standards | ||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 1 | 2 | 3 | 4 | 5 | 6 | |
Quality | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | |||||||
Acceptability | x | x | x | x | x | x | x | x | x | x | x | x | x | x | ||||||||||
Equity | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | |||||||||
Human rights | x | x | x | x | x | x | x | x | x | x | x | x | x | |||||||||||
Value to participants | x | x | x | x | x | x | x | x | x | x | x | x | x | |||||||||||
Scope | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | ||||||
Recommendations | x | x | x | x | x | |||||||||||||||||||
Credibility | x | x | x | x | x | x | ||||||||||||||||||
Cost-effectiveness | x | x | x |
See Supplementary Table 5 for key to numerical references.